Lg. Menon et al., EFFECT OF RASAYANAS IN THE INHIBITION OF LUNG METASTASIS INDUCED BY B16F-10 MELANOMA-CELLS, Journal of experimental & clinical cancer research, 16(4), 1997, pp. 365-368
Five rasayanas and one of the ingredients Emblica officinalis (EO), we
re studied for their antimetastatic activity using B16F-10 melanoma ce
lls in C57BL/6 mice. Simultaneous oral administration (50mg/animal/dos
e) of Brahma Rasayana (BR) and Aswagandha Rasayana (AR) significantly
reduced the lung tumour nodule formation by 71.28% (P < 0.001) and 55.
6% (P < 0.001), respectively. Similarly, the lung collagen hydroxyprol
ine content and the serum sialic acid levels were also low in BR treat
ed (4.8 +/- 0.97 ug/mg protein; 35.6 +/- 2.6 ug/ml serum) and AR treat
ed animals (6.15 +/- 0.5 ug/mg protein; 56.3 +/- 8.7 ug/ml serum) comp
ared to the untreated controls (10.43 +/- 0.7 ug/mg protein; 161.3 +/-
9.5 ug/ml serum). Narasimha Rasayana (NR), Amrithaprasam (AP), Chyava
naprasam (CP) and Emblica extract (EO) administration had no significa
nt effect in the reduction of lung nodule formation and lung hydroxypr
oline and serum sialic acid contents which was similar to that of untr
eated controls. Life span of BR, AR and NR treated animals was found t
o be significantly increased. These results indicate that BR and AR po
ssess antimetastatic activity against melanoma cells.